Eligibility Details:
Inclusion Criteria:
- Are overtly healthy males or females, apart from dyslipidemia
- Male participants must agree to adhere to contraception restrictions
- Female participants must be of nonchildbearing potential and include those who are
infertile due to surgical sterilization or those who are postmenopausal
- Are between 18 (20 for Japanese participants) and 65 years of age, inclusive
- Have a body mass index (BMI) >18.5 and <40 kilograms per meter squared (kg/m²)
- Have clinical laboratory test results within normal reference range, or acceptable
deviations per investigator discretion
Parts A and C ONLY
- Have a fasting triglyceride (TG) level that is 135 to 499 milligrams per deciliter
(mg/dL), inclusive, at both screening and Day -1
- Have a fasting low density lipoprotein cholesterol (LDL-C) level greater than or equal
to (≥) 70 mg/dL, inclusive, at screening and Day -1
- Have had a stable body weight for the 3 months prior to randomization (<5% body weight
change)
- Have not modified diet or adopted any nutritional lifestyle modification within 3
months prior to randomization
Part B ONLY
- Are first-generation Japanese, defined as follows: the participant, the participant's
biological parents, and all of the participant's biological grandparents must be of
exclusive Japanese descent and born in Japan
Exclusion Criteria:
- Are taking or have started taking Proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors within 3 months prior to randomization; or statins, fibrates, or
niacin ≤1000 mg/day within 8 weeks prior to randomization; or niacin >1000 milligrams
per day (mg/day) within 16 weeks prior to randomization; or any other lipid-lowering
agents within 1 month prior to randomization
- Are taking or have started taking a beta-blocker, antiarrhythmic, non-dihydropyridine
calcium channel blocker, ivabradine, or any other heart rate lowering agent within 1
month or 5 half-lives prior to randomization, whichever is longer
- Have a diagnosis of diabetes mellitus (type 1 diabetes mellitus or type 2 diabetes
mellitus) or have 1 of the following at screening: fasting plasma glucose
concentration ≥126 mg/dL (7.0 millimoles per liter [mmol/L]) OR a glycated hemoglobin
level ≥6.5% (48 millimoles per mole [mmol/mol])
- Have previously completed or withdrawn from this study or any other study
investigating LY3475766, and have previously received the investigational product
- Have known allergies to LY3475766, related compounds, or any components of the
formulation, or history of significant atopy
- Have a seated heart rate ≤50 beats per minute
- Have clinically significant abnormal electrocardiogram (ECG) results constituting a
risk while taking the investigational product, as determined by the investigator
- Have an abnormal blood pressure (BP) as determined by the investigator
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
